Press Releases Filter By Year 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 August 1, 2019 Valneva Reports H1 2019 Results Marked by Strong Operational Performance and Major Corporate Progress July 29, 2019 Valneva Announces Formation of Scientific Advisory Board July 25, 2019 CEPI awards up to US$23.4 million to Valneva for late-stage development of a single-dose chikungunya vaccine July 16, 2019 Valneva Announces Drawdown of Further €10 million from its Existing European Investment Bank Loan July 3, 2019 Valneva: Renowned Vaccinologist Dr. Stanley Plotkin to Present at R&D Investor Day in New York City on July 9th July 2, 2019 Valneva Submits Delisting Application to the Vienna Stock Exchange July 1, 2019 Valneva Initiates Second Phase 2 Study for its Lyme Disease Vaccine Candidate VLA15 June 28, 2019 Valneva Shareholders Approve all Resolutions Recommended by the Management Board at the Annual General Meeting June 20, 2019 Valneva Announces Mutual Agreement with GSK to End Strategic Alliance Agreement; Regains Control of R&D June 12, 2019 Valneva Reports Successful Outcome of Phase 2 Run-In for its Lyme Disease Vaccine Candidate 1 2 3 … 31
August 1, 2019 Valneva Reports H1 2019 Results Marked by Strong Operational Performance and Major Corporate Progress
July 25, 2019 CEPI awards up to US$23.4 million to Valneva for late-stage development of a single-dose chikungunya vaccine
July 16, 2019 Valneva Announces Drawdown of Further €10 million from its Existing European Investment Bank Loan
July 3, 2019 Valneva: Renowned Vaccinologist Dr. Stanley Plotkin to Present at R&D Investor Day in New York City on July 9th
June 28, 2019 Valneva Shareholders Approve all Resolutions Recommended by the Management Board at the Annual General Meeting
June 20, 2019 Valneva Announces Mutual Agreement with GSK to End Strategic Alliance Agreement; Regains Control of R&D
June 12, 2019 Valneva Reports Successful Outcome of Phase 2 Run-In for its Lyme Disease Vaccine Candidate
